Early access
Sign in
Taking people in DenmarkPhase 2

MR scan with a labelled pyruvate tracer in pancreatic cancer patients

Tests an MR scan using hyperpolarised pyruvate in adults with pancreatic cancer.

Key facts

Who runs it
Aarhus Universitet
Where
Aarhus N, DenmarkSee the site
Registry title
MR-HYPERPOLARISATION SCANNING WITH HYPERPOLARISED PYRUVATE (13C) IN PANCREATIC CANCER PATIENTS – A FEASIBILITY STUDY
Status
Recruiting
Phase
Phase 2
People taking part
16 people, planned
Started
13 Sept 2024
Planned end
31 Dec 2024
Type of study
Interventional
Record updated
25 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with pancreatic cancer that cannot be removed by surgery, or that has come back. They are about to start, or are already having, chemotherapy.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Pancreatic adenocarcinoma confirmed by tissue or cell tests. It is inoperable (metastatic, locally advanced or localised) or has relapsed.
Earlier treatment
Scheduled for first-line palliative chemotherapy of any type, or has already had at least 4 cycles of chemotherapy. The exclusion list also says previous or current radiotherapy or chemotherapy.
Biomarker or test result
Blood counts, liver and kidney tests must be adequate, for example ANC at least 1.500/uL and bilirubin under 1.5 x UNL. WHO performance status 0-2.

Main reasons for not taking part

  • Cannot have contrast-enhanced MRI or CT
  • Expected remaining survival under 3 months
  • Serious uncontrolled medical condition, for example uncontrolled heart disease or diabetes
  • History of pancreatitis, or acute or chronic liver disease including cirrhosis
  • Intolerant to pyruvate

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Patients with inoperable (metastatic, locally advanced or localised)or relapsedhistologically or cytologically verified pancreatic adenocarcinoma
  • Scheduled for first-line palliative chemotherapy of any type or having received at least 4 cycles of chemotherapy
  • At least 18 years of age
  • WHO performance status 0-2
  • Adequate hematologic and organ function, i.e. ANC at least 1.500/uL Platlet count >100/uL Se bilirubin <1.5 UNL ASAT, ALAT and AP up to 2.5 x UNL, up to 5 x UNL with liver metastases Se creatinine up to 1.5 x UNL or creatinine clearance at least 30 ml/min INR and aPTT at most 1.5 x UNL, except for patients on AK treatment
  • Women who are not postmenopausal or surgically sterile must have a negative serum or urin pregnancy test performed at time of inclusion in the study. Safe and highly effective contraception must be used throughout the study meaning either hormonal anti-conception or an anti-fertility intrauterine device. If the partner is non fertile or the patient has no sexual activities, this is also accepted
  • Danish speaking
  • Able and willing to comply after informed consent

Who cannot take part

  • Not able or willing to receive chemotherapy
  • Previous or current radiotherapy or chemotherapy
  • Uncontrolled serious medical condition, such as uncontrolled heart disease, uncontrolled diabetes, intestinal obstruction, uncontrolled hypertension, or recent cerebral ischemia or cardiac events
  • History of acute or chronic pancreatitis
  • Acute or chronic liver disease incl. cirrhosis
  • Contraindications to contrast enhanced MRI
  • Predicted remaining survival <3 months
  • Contraindication to contrast enhanced CT
  • Patients not willing to participate
  • Intolerant to Pyruvate

Where in Denmark

  • Aarhus UniversitetshospitalAarhus N, DenmarkTaking people

About the trial

What the trial wants to find out

To optimise the MR-hyperpolarisation scanning technique in patients using a dose of 13C-Pyruvate established as safe in previous phase I/II-studies. To obtain baseline data on 13C-Pyruvate MR-hyperpolarisation signals in selected anatomical sites including tumorous pancreas, non-tumorous pancreas, liver metastases and normal liver. To confirm safety and feasibility of infusion of 13C-Pyruvate in patients with pancreatic cancer. To explore correlations between 13C-Pyruvate MR-hyperpolarisation signals and evidence of clinical response to chemotherapy to be tested in further phase II-studies.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
MR-HYPERPOLARISATION SCANNING WITH HYPERPOLARISED PYRUVATE (13C) IN PANCREATIC CANCER PATIENTS – A FEASIBILITY STUDY
Plain-language title
MR scan with a labelled pyruvate tracer in pancreatic cancer patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
25 September 2025